Mazdutide: Research, Dosing, and Where to Buy in 2026

What is Mazdutide?

Research compound aggregated from creator and literature mentions. No direct disease-treatment claims are made on this page.

What is Mazdutide researched for?

GLP-1/glucagon dual agonist; alternative to Lilly/Novo GLPs because owned by a Chinese company without US legal pressure.

Mazdutide Dosing Protocols

The entries below are transcript-derived dosing mentions. They are preserved for research context and are not medical advice.

Where to Buy Mazdutide in 2026

Side Effects and Safety

What Experts Say

1 expert across our source library discuss Mazdutide. Each entry is that expert’s most context-rich mention: click to watch it at the exact timestamp in the original video. Quotes are also emitted as Schema.org Quotation JSON-LD for AI assistants.

1. Tanner / Nyle Nayga · Best PED Use (Competitive vs. Lifestyle) & All Things...Watch @ 26:32 ↗

   “Mazda Tide is owned by a Chinese company. They might not have legal teams in the US pressing down on them. So, if you wanted an alternative that might be around a little bit longer”

User Reviews

Research Efficacy Snapshot

Published efficacy percentages cited in PubMed trials and named-expert reports about Mazdutide. Each line links to the original source.

• "Significantly greater reductions in body weight were achieved with mazdutide than with dulaglutide, with a least-squares mean treatment difference of -3.78% for 4 mg mazdutide and -5.76% for 6 mg mazdutide (both P < 0.0001), relative to dulaglutide." · Guo L et al, 2026 PubMed
• "Moreover, significantly more participants who received mazdutide 4 mg or 6 mg reached the composite end point of HbA1c < 7.0% with a body-weight reduction of at least 5% at week 28 (both P < 0.0001), compared with those who received dulaglutide." · Guo L et al, 2026 PubMed
• "At week 24, mazdutide significantly reduced HbA1c versus placebo (primary endpoint): -1.57% with mazdutide 4 mg and -2.15% with mazdutide 6 mg, versus -0.14% with placebo, with treatment differences of -1.43% and -2.02% (both P < 0.0001)." · Zhu D et al, 2026 PubMed
• "Weight loss from baseline at week 24 occurred with -5.61% (4 mg) and -7.81% (6 mg) versus -1.26% (placebo) (both P < 0.0001)." · Zhu D et al, 2026 PubMed
• "The two primary end points were the percentage change in body weight from baseline and a weight reduction of at least 5% at week 32, as assessed in a treatment-policy estimand analysis (which assessed effects regardless of early discontinuation of mazdutide or placebo and the initiation of new antiobesity therapies)." · Ji L et al, 2025 PubMed
• "The incidence of adverse events leading to discontinuation of the trial regimen was 1.5% with the 4-mg mazdutide dose, 0.5% with the 6-mg mazdutide dose, and 1.0% with placebo." · Ji L et al, 2025 PubMed
• "Mean changes in HbA1c from baseline to week 20 ranged from -1.41% to -1.67% with mazdutide (-1.35% with dulaglutide and 0.03% with placebo; all P < 0.0001 vs." · Zhang B et al, 2024 PubMed
• "Mean percent changes in body weight from baseline to week 20 were dose dependent and up to -7.1% with mazdutide (-2.7% with dulaglutide and -1.4% with placebo)." · Zhang B et al, 2024 PubMed
• "At week 20, participants receiving mazdutide were more likely to achieve HbA1c targets of <7.0% (53 mmol/mol) and ≤6.5% (48 mmol/mol) and body weight loss from baseline of ≥5% and ≥10% compared with placebo-treated participants." · Zhang B et al, 2024 PubMed
• "The most common adverse events with mazdutide included diarrhea (36%), decreased appetite (29%), nausea (23%), vomiting (14%), and hypoglycemia (10% [8% with placebo])." · Zhang B et al, 2024 PubMed

Research and Studies

8 PubMed-indexed papers reference Mazdutide. Top 8 shown.

Legal Status

Frequently Asked Questions